Compare The Coca-Cola Co K (KO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Sana Biotechnology Inc — how do they compare? The Coca-Cola Co K trades at $86.97 (market cap $372.08B), while Sana Biotechnology Inc trades at $3.81 (market cap $1.13B). The key difference: The Coca-Cola Co K is far larger — about 329.3× Sana Biotechnology Inc's market cap, and The Coca-Cola Co K pays a 2.45% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| KO | SANA | |
|---|---|---|
Market Cap | $372.08B | $1.13B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $89.08 | $5.92 |
52-Week Low | $65.67 | $2.68 |
Enterprise Value | $399.26B | $1.05B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $87.27, up 0.46% today, with a bullish technical signal and consistent earnings beats. The company shows strong profitability with a 28.56% net margin and 44.23% ROE, supported by stable revenue growth to $47.94B in 2025. Recent news highlights institutional accumulation and dividend reliability, with the stock near key resistance at $87.
Outlook remains positive with a $95.83 consensus price target and 60% analyst buy ratings, though high valuation multiples (P/E 25.97) and debt levels pose risks. The stock offers steady income with a $0.53 quarterly dividend and growth potential from global demand trends, but faces headwinds from regional volatility and competitive pressures.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
